Closing

Do SGLT2 inhibitors improve all-cause mortality versus placebo?

Mostly studied in chronic kidney disease. Also asked against other treatments.

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

A coin flip. So far, the results disagree.

NoUnsureYes
Belief
0.50 (range 0.00–0.55)
Trials for
5
Trials against
4
Inconclusive
3

Already under way

The evidence so far

Registered trials
106
With posted results
23
Published papers
7

Of 61 decided analyses: 14 favor sglt2 inhibitors, 38 find no difference, 9 favor the comparator.

Papers

Trials

See every trial in the evidence map →